Eli Lilly and Company Cash Flow-to-Debt Ratio
Eli Lilly and Company cash flow-to-debt ratio. Eli Lilly and Company (LILY34) has a Cash Flow-to-Debt Ratio of 0.06x as of March 2026, meaning its operating cash flow of R$5.33 Billion could theoretically repay 0% of its total liabilities (R$85.38 Billion) in one year. Check LILY34 cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Eli Lilly and Company (2014–2025)
Cash flow-to-debt ratio of Eli Lilly and Company from 2014 to 2025. Historical debt coverage capacity for Eli Lilly and Company across 12 annual periods. Check earnings quality score of Eli Lilly and Company to evaluate the quality of earnings relative to operating cash generation.
Eli Lilly and Company Cash Flow-to-Debt Ratio by Year (2014–2025)
Eli Lilly and Company cash flow-to-debt ratio by year from 2014 to 2025. Year-by-year debt coverage analysis for Eli Lilly and Company. For the full cash flow conversion analysis, see Eli Lilly and Company cash flow conversion.
| Year | CF-to-Debt Ratio | Operating CF (BRL) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.20x | R$16.81 Billion | R$85.94 Billion | ▲ +43.0% |
| 2024 | 0.14x | R$8.82 Billion | R$64.44 Billion | ▲ +27.3% |
| 2023 | 0.11x | R$5.71 Billion | R$53.14 Billion | ▼ -41.1% |
| 2022 | 0.18x | R$7.08 Billion | R$38.84 Billion | ▼ -0.4% |
| 2021 | 0.18x | R$7.26 Billion | R$39.65 Billion | ▲ +15.5% |
| 2020 | 0.16x | R$6.50 Billion | R$40.99 Billion | ▲ +20.2% |
| 2019 | 0.13x | R$4.84 Billion | R$36.68 Billion | ▼ -18.7% |
| 2018 | 0.16x | R$5.52 Billion | R$34.08 Billion | ▼ -3.6% |
| 2017 | 0.17x | R$5.62 Billion | R$33.39 Billion | ▼ -14.0% |
| 2016 | 0.20x | R$4.85 Billion | R$24.80 Billion | ▲ +38.4% |
| 2015 | 0.14x | R$2.96 Billion | R$20.98 Billion | ▼ -33.7% |
| 2014 | 0.21x | R$4.46 Billion | R$20.92 Billion | — |